|Sponsor||Institut de Recherches Internationales Servier (I.R.I.S)|
|Active Substance Code||S068587|
|Results are not yet available.|
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
UCART-19 is anti-CD-19 allogenic CAR-T product developed based on exclusive license granted by Cellectis to Servier. UCART-19 uses Cellectis’ technologies, including TALEN® gene-editing technologies